DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Ultragenyx Announces Planned Transition Of Chief Financial Officer

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that Shalini Sharp will step down from her

Benzinga · 03/03/2020 21:20

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that Shalini Sharp will step down from her position as Chief Financial Officer and Executive Vice President by September 2, 2020. At such time, Ms. Sharp plans to focus her time on her family and her role as an advisor and board member for various biotechnology companies. Ultragenyx will initiate a search for a successor, and Ms. Sharp will continue to serve as CFO until a replacement is found or until September 2, 2020. After that date, Ms. Sharp will stay on for six months to aid with the transition.